IntelGenx Technologies Corp. Appoints New Chief Financial Officer

August 09, 2007

SAINT LAURENT, QUEBEC--(CCNMatthews - Aug. 9, 2007) - IntelGenx Technologies Corp. (OTCBB:IGXT), a drug delivery company creating new delivery technologies for generic pharmaceutical markets, announced today the appointment of Gino Di Iorio as its Chief Financial Officer, effective immediately.

In a career spanning 15 years, Mr. Di Iorio has acquired operational management capabilities, and valuable experience in the bio-tech, advertising and telecommunication industries. He has held CFO and Finance Director positions for Viropro Inc., Sitel Corp. and Draft Inc. traded on the NASDAQ and New York Stock Exchanges.

"Through this appointment, IntelGenx is even better positioned to optimize the value of its assets and those of its shareholders in the short- and long-term period," said Horst G. Zerbe, President and CEO, IntelGenx.

About IntelGenx Technologies

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of osteoarthritic, pain management, hypertension and smoking cessation. Since January 2007, IntelGenx has been trading on the OTCBB.

To learn more about IntelGenx, please visit the Company's website at http://www.intelgenx.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Pursuant to a June 1, 2007 contract, Consulting For Strategic Growth1, Ltd. ("CFSG1") provides IntelGenx Corp. ("the Company") with consulting, business advisory, investor relations, public relations and corporate development services. Independent of CFSG1's receipt of cash compensation from the Company, CFSG1 may choose to purchase the Company's common stock and thereafter liquidate those securities at any time it deems appropriate to do so.

FOR FURTHER INFORMATION PLEASE CONTACT:

IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
(514) 331-7440 (ext. 201)
(514) 331-0436 (FAX)
Email: horst@IntelGenx.com
Website: www.intelgenx.com


Investor Relations:
Consulting for Strategic Growth 1
Stanley Wunderlich, CEO
1-800-625-2236
(212) 337-8089 (FAX)
Email: info@cfsg1.com



Media Relations:
Consulting for Strategic Growth 1
Daniel Stepanek
(212) 896-1202
(212) 697-0910 (FAX)
Email: dstepanek@cfsg1.com
Website: www.cfsg1.com


Source: CCN Matthews (August 9, 2007 - 9:30 AM EST)

News by QuoteMedia
www.quotemedia.com